Our first guest today is National Commander of the American Legion Bill Oxford. Today he will discuss National Poppy Day, Oxford wants to ensure time-honored traditions continue. He is encouraging all patriotic Americans to wear a red poppy on May 28, which is National Poppy Day.
“The red poppy is a symbol of remembrance and hope,” Oxford said. “Memorial Day is another important observance on May 31. The entire American Legion Family believes that our country must never forget the fallen heroes who have made our way of life possible. Even if we must maintain social distance, gather outdoors or attend a virtual service, it is important to honor the men and women who lost their lives in defense of this great country that we call ‘America.’”
The American Legion is the nation’s largest veterans’ service organization with nearly two million members and more than 12,000 posts worldwide. Legionnaires are involved in community-based support of veterans, service members, and their families. The American Legion is strongly committed to helping veterans and military families with its outreach programs and lobbying efforts, as a new generation of returning veterans reintegrate into the community. For more information go to: www.legion.org
Our second guests today are Dr. Jorge Gomez, a medical oncologist in the thoracic oncology program at Mount Sinai Hospital in New York. The topic is Dr. Jorge Gomez, a medical oncologist and a new campaign that hopes to educate the public about biomarker testing. If you’re living with non-small cell lung cancer, one conversation with your doctor could make a difference in your treatment.
Joining Dr. Gomez is Andrea Ferris, President, and CEO of LUNGevity Foundation and member of the Board of Directors. In her role as President and CEO of LUNGevity,
LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, is launching No One Missed, a multi-year, integrated campaign to drive comprehensive biomarker testing in non-small cell lung cancer (NSCLC)—the most common type of lung cancer—to help people pursue optimal care.1 While current guidelines recommend comprehensive biomarker testing, significant gaps remain, potentially limiting the number of individuals receiving critical test results to help inform treatment decisions. For more information go to https://lungevity.org/